NeuroBo Pharmaceuticals Files 8-K
Ticker: MTVA · Form: 8-K · Filed: May 22, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
Related Tickers: NRBO
TL;DR
NeuroBo Pharma dropped an 8-K, check it for deets.
AI Summary
On May 22, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signifies an official update from NeuroBo Pharmaceuticals to the SEC, potentially containing material information for investors regarding the company's operations or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosed negative or positive financial events, making the risk level low based on this excerpt.
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- Gemphire Therapeutics Inc. (company) — Former company name
- May 22, 2024 (date) — Date of earliest event reported
FAQ
What specific "Other Events" are reported in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" reported in the 8-K filing.
What is the significance of filing "Financial Statements and Exhibits"?
Filing "Financial Statements and Exhibits" typically means the company is providing updated financial information or supporting documents as required by the SEC.
When was NeuroBo Pharmaceuticals, Inc. previously known as Gemphire Therapeutics Inc.?
The company changed its name from Gemphire Therapeutics Inc. on March 31, 2015.
What is the principal executive office address for NeuroBo Pharmaceuticals, Inc.?
The principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
What is the IRS Employer Identification Number for NeuroBo Pharmaceuticals, Inc.?
The IRS Employer Identification Number for NeuroBo Pharmaceuticals, Inc. is 47-2389984.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-05-22 08:30:16
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240522x8k.htm (8-K) — 43KB
- nrbo-20240522xex99d1.htm (EX-99.1) — 38KB
- nrbo-20240522x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240522xex99d1001.jpg (GRAPHIC) — 13KB
- nrbo-20240522xex99d1002.jpg (GRAPHIC) — 17KB
- nrbo-20240522xex99d1003.jpg (GRAPHIC) — 16KB
- nrbo-20240522xex99d1004.jpg (GRAPHIC) — 20KB
- nrbo-20240522xex99d1005.jpg (GRAPHIC) — 54KB
- 0001558370-24-008555.txt ( ) — 403KB
- nrbo-20240522.xsd (EX-101.SCH) — 3KB
- nrbo-20240522_lab.xml (EX-101.LAB) — 15KB
- nrbo-20240522_pre.xml (EX-101.PRE) — 9KB
- nrbo-20240522x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On May 22, 2024, NeuroBo Pharmaceuticals, Inc. issued a press release announcing that pre-clinical data suggests that DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in combination with semaglutide (Wegovy), improves liver fibrosis and demonstrates additive hepatoprotective effects in pre-clinical metabolic dysfunction-associated steatohepatitis (MASH) models compared to either treatment alone. Members of the Dong-A ST Research Center and Contract Research Organization, Gubra, will present the data in two poster presentations at the EASL Congress 2024, taking place June 5-8, in Milan, Italy, as well as virtually. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated May 22, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: May 22, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer